Azerbaijan vs China: Treatment success rate for patients treated for MDR-TB
Azerbaijan
67.0%
in 2022
China
68.0%
in 2022
Azerbaijan rank
106th
China rank
104th
Treatment success rate for patients treated for MDR-TB over time
- Azerbaijan
- China
How they compare
China currently reports 68.0% against 67.0% in Azerbaijan, a difference of 1.0%.
The two have swapped places 1 time across 15 shared years of data; in 2008 it was Azerbaijan ahead.
Azerbaijan ranks 106th and China ranks 104th of 163 countries.
Azerbaijan has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Azerbaijan | China | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 65.5% | 46.0% | 19.5% | Azerbaijan |
| 2010s | 58.8% | 48.4% | 10.4% | Azerbaijan |
| 2020s | 64.3% | 61.7% | 2.7% | Azerbaijan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher treatment success rate for patients treated for mdr-tb, Azerbaijan or China?
- China, at 68.0% against 67.0% in Azerbaijan as of 2022.
- What is the difference in treatment success rate for patients treated for mdr-tb between Azerbaijan and China?
- 1.0%, with China ahead.
- How many years of comparable data are there for Azerbaijan and China?
- 15 years are reported by both, from 2008 to 2022.
- How do Azerbaijan and China rank globally for treatment success rate for patients treated for mdr-tb?
- Azerbaijan ranks 106th and China ranks 104th of 163 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Treatment success rate for patients treated for MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.